Antibody discovery, development, and optimization
End-to-end antibody discovery from the lab that has done it 3,000 times.
Thirty-five years. One team from immunization to optimized lead. B cell Select® finds functional antibodies early; AI-enabled analysis informs every candidate decision.
Antibody discovery, from a lab with 35 years behind it.
One team runs your program from target to optimized lead. Our technology works inside it.
Antibody Discovery Programs
End-to-end discovery, development, and optimization, customized to your target.
- Advanced wet lab with LensAI™ analysis on every candidate
- 20+ publicly disclosed client antibodies have advanced from our lab into clinical development. Publicly disclosed programs only; additional client antibodies have advanced under partner confidentiality.
- B cell Select® >98% discovery success rate*
- B cell Llama™, hybridoma, and yeast display discovery
- Flexible engagement models
Our technology
ReefIQ™ and LensAI™, powered by HYFT® technology.
- ReefIQ™ connects your discovery data and adds biological context; the one product available to license on its own
- LensAI™, our AI analysis platform, delivered inside every program: epitope mapping, paratyping, developability, immunogenicity, candidate evaluation
- Powered by HYFT® technology, which reasons over the patterns evolution has conserved: 25B+ biological relationships.
In the spotlight
ReefIQ at AMD Advancing AI 2026
MindWalk highlighted ReefIQ and its partnership with AMD in a leading area of life science technology: the data, compute, and infrastructure powering AI drug discovery at speed and scale. ReefIQ connects fragmented research data with biological context to strengthen AI reasoning.
B cell Llama™ VHH Discovery
MindWalk expanded its antibody discovery portfolio with B cell Llama™, a direct B cell VHH discovery platform that accesses the in vivo-matured camelid immune repertoire. The platform supports VHH discovery for bispecific, multispecific, and other therapeutic formats.
MindWalk obtains binding commitment for US $30M unsecured credit facility to fund biologics programs and ReefIQ commercial expansion
Fixed 7.00% rate. No financial maintenance covenants. No warrants or equity conversion features. No dilution to existing shareholders.
Epitope Mapping
Molecular precision aligned with x-ray crystallography. A recent LensAI case study shows computational insights reaching crystallographic-level accuracy for epitope mapping, highlighting how predictive context can strengthens experimental confidence.
CaseXCase
A series dedicated to LensAI in action. Each example applies biointelligence across discovery workflows—explore how analysis supports insight and measurable outcomes.
Darwin Inspired
Our brand is shaped by the principles of Darwin's daily walk of observation. MindWalk unites science and technology—a shared path shaped by curiousity and connection.
Integrated capabilities.
Connected around
your challenge.
We focus on the outcome your program needs and build the approach around delivering it. One multidisciplinary team stays with your program from design through molecule delivery, with direct access to the people doing the work. We offer flexible partnership structures and business terms to fit the program.
Advanced lab
B cell Select® function-first discovery, hybridoma, yeast display, and B cell Llama™; characterization, engineering, optimization, and production. Thirty-five years, 3,000+ programs.
LensAI™
Our AI analysis platform: candidate risk, developability, and immunogenicity, with the evidence behind every rank. Delivered inside every program.
ReefIQ™
Connects your discovery data across teams and systems and adds biological context for AI reasoning.
Research highlights & innovation news
See latest updates: clinical trial, publications and patents
Across modalities, applications, and stages.
Partners with molecules in the clinic
“The MindWalk Rapid Prime immunization method and their downstream antibody discovery technology proved pivotal to Acumen's success, enabling timely identification of our human immunotherapeutic, sabirnetug, currently in Phase 2 clinical trials.”
Acumen Pharmaceuticals
“We partnered with MindWalk to generate specific binders against targets in autoimmunity and inflammation. Their proven expertise and customized discovery approach stood out immediately, and results from both their laboratory and LensAI platform exceeded expectations.”
GentiBio
“The B cell Select platform was central in developing our lead immunoinhibitory receptor drug candidates, which are now in phase I/II clinical trials. MindWalk's strategic approach, deep experience and technical know-how were essential to our discovery efforts.”
OncoResponse
“MindWalk’s LensAI platform, powered by HYFT technology, was central to optimizing our Pan-Amyloid Immunotherapy candidates for neurodegenerative disease. Their in silico screening, developability analysis, and protein engineering accelerated our discovery process and strengthened candidate performance.”
Amyl Therapeutics
The Vault™
Partner-ready antibody and vaccine assets
In-license or co-develop candidates our lab has already discovered and optimized.
Case Studies
Explore validated insights that redefine workflows and optimize discovery success.
Antibody Discovery Deep Dives
Explore the species, methods, and strategies behind complex antibody discovery.
Blogs
Explore latest ideas reshaping the future of discovery.
Powered by experts
MindWalk, formerly ImmunoPrecise Antibodies, is an antibody discovery company. Thirty-five years at the bench: scientists first, technologists alongside, delivering integrated programs from design through molecule delivery.
Tell us about your target.
A scientist, not a sales rep, replies within two business days.
Upcoming Events
Join us at an upcoming event.
BioTechX Europe 2026
Basel, Switzerland
Oct 6-8, 2026
Festival of Biologics 2026
Basel, Switzerland
Oct 13-15, 2026
AI-Driven Drug Discovery Summit 2026
Boston USA
Oct 27-29, 2026
PEGS Europe 2026
Lisbon, Portugal
Nov 17-19, 2026
Antibody Engineering & Therapeutics 2026
San Diego USA
Dec 13-16, 2026